Defining NASH from a multi-omics systems biology perspective
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Defining NASH from a multi-omics systems biology perspective. / Niu, Lili; Sulek, Karolina; Vasilopoulou, Catherine G.; Santos, Alberto; Wewer Albrechtsen, Nicolai J.; Rasmussen, Simon; Meier, Florian; Mann, Matthias.
I: Journal of Clinical Medicine, Bind 10, Nr. 20, 4673, 2021.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Defining NASH from a multi-omics systems biology perspective
AU - Niu, Lili
AU - Sulek, Karolina
AU - Vasilopoulou, Catherine G.
AU - Santos, Alberto
AU - Wewer Albrechtsen, Nicolai J.
AU - Rasmussen, Simon
AU - Meier, Florian
AU - Mann, Matthias
N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021
Y1 - 2021
N2 - Non-alcoholic steatohepatitis (NASH) is a chronic liver disease affecting up to 6.5% of the general population. There is no simple definition of NASH, and the molecular mechanism underlying disease pathogenesis remains elusive. Studies applying single omics technologies have enabled a better understanding of the molecular profiles associated with steatosis and hepatic inflammation—the commonly accepted histologic features for diagnosing NASH, as well as the discovery of novel candidate biomarkers. Multi-omics analysis holds great potential to uncover new insights into disease mechanism through integrating multiple layers of molecular information. Despite the technical and computational challenges associated with such efforts, a few pioneering studies have successfully applied multi-omics technologies to investigate NASH. Here, we review the most recent technological developments in mass spectrometry (MS)-based proteomics, metabolomics, and lipidomics. We summarize multi-omics studies and emerging omics biomarkers in NASH and highlight the biological insights gained through these integrated analyses.
AB - Non-alcoholic steatohepatitis (NASH) is a chronic liver disease affecting up to 6.5% of the general population. There is no simple definition of NASH, and the molecular mechanism underlying disease pathogenesis remains elusive. Studies applying single omics technologies have enabled a better understanding of the molecular profiles associated with steatosis and hepatic inflammation—the commonly accepted histologic features for diagnosing NASH, as well as the discovery of novel candidate biomarkers. Multi-omics analysis holds great potential to uncover new insights into disease mechanism through integrating multiple layers of molecular information. Despite the technical and computational challenges associated with such efforts, a few pioneering studies have successfully applied multi-omics technologies to investigate NASH. Here, we review the most recent technological developments in mass spectrometry (MS)-based proteomics, metabolomics, and lipidomics. We summarize multi-omics studies and emerging omics biomarkers in NASH and highlight the biological insights gained through these integrated analyses.
KW - Biomarker discovery
KW - Liver disease
KW - Machine learning
KW - Multi-omics
KW - NAFLD
KW - Systems biology
U2 - 10.3390/jcm10204673
DO - 10.3390/jcm10204673
M3 - Review
C2 - 34682795
AN - SCOPUS:85116795098
VL - 10
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
SN - 2077-0383
IS - 20
M1 - 4673
ER -
ID: 283756576